Header Logo

Connection

LEO LUZNIK to CTLA-4 Antigen

Back to Details
This is a "connection" page, showing publications LEO LUZNIK has written about CTLA-4 Antigen.
LEO LUZNIK
Connection Strength
0.150
CTLA-4 Antigen
  1. A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure. Clin Cancer Res. 2018 08 01; 24(15):3519-3527.
    View in: PubMed
    Score: 0.150
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.